Eli Lilly Stock Hits Record High on Positive Clinical Trial Results for Weight Loss Drug
Shares of Eli Lilly rose to a record high following positive Phase 3 trial results for its investigational weight loss drug, Retatrutide. The trials showed significant average body weight reductions and improvements in obesity-related conditions.
Tickers: $LLY